Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia

Hematology/Oncology Clinics of North America

Volumn 12, Issue 1, 1998, Pages 123-150

  Porter, D L ^a   Antin, J H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CYTOGENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA REMISSION; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT PLANNING;

EID: 0031931827     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70500-1     Document Type: Article

References (134)

1. E. Alyea R. Soiffer C. Murray Adoptive immunotherapy following allogeneic bone marrow transplantation (BMT) with donor lymphocytes depleted of CD8+ T cells Blood 86 1995 293a
2. J. Antin Graft-versus-leukemia: No longer an epiphenomenon Blood 82 1993 2273 2277
3. J. Antin J. Ferrara Cytokine dysregulation and acute graft-versus-host disease Blood 80 1992 2964 2968
4. J. Antin B. Bierer B. Smith Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies Blood 78 1991 2139 2149
5. J. Apperley F. Mauro J. Goldman Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Importance of a graft-versus-leukaemia effect Br J Haematol 69 1988 239 245
6. W. Arcese J. Goldman E. D'Arcangelo Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia Blood 82 1993 3211 3219
7. M. Baker N. Altman E. Podack The role of cell mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice J Exp Med 183 1996 2645 2656
8. M. Baker E. Podack R. Levy Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice Biology of Blood and Marrow Transplantation 1 1995 69 73
9. F. Balkwill Interferons Balkwill F. Cytokines in Cancer Therapy 1989 Oxford University Press Oxford 8 53
10. B. Bar A. Schattenberg E. Mensink Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation J Clin Oncol 11 1993 513 519
11. D. Barnes J. Loutit Treatment of murine leukaemia with X-rays and homologous bone marrow Br J Haematol 3 1957 241 252
12. D. Barnes M. Corp J. Loutit Treatment of murine leukaemia with X rays and homologous bone marrow. Preliminary communication Br Med J 2 1956 626 630
13. A. Barrett D. Mavroudis J. Molldrem Optimizing the dose and timing of lymphocyte add-back in T-cell depleted BMT between HLA-identical siblings Blood 88 1996 460a
14. W. Bensinger C. Weaver F. Appelbaum Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor Blood 85 1995 1655 1658
15. M. Bocchia T. Korontsvit Q. Xu Specific human cellular immunity to bcr-abl oncogene derived peptides Blood 87 1996 3587 3592
16. M. Bocchia P. Wentworth S. Southwood Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules Blood 85 1995 2680 2684
17. C. Bonini S. Verzeletti P. Servida Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT Blood 84 1994 110a
18. M. Braun B. Lowin L. French Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease J Exp Med 183 1996 657 661
19. D. Bunjes M. Theobald B. Hertenstein Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells Bone Marrow Transplant 15 1995 713 719
20. W. Chen D. Peace D. Rovira T-cell immunity to the joining region of p210 BCR-ABL protein Proc Natl Acad Sci USA 89 1992 1468 1472
21. R. Collins Z. Rogers M. Bennett Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression Bone Marrow Transplant 10 1992 391 395
22. R. Collins O. Shpilberg W. Drobyski Donor leukocyte infusion (DLI) for post–bone marrow transplant (BMT) relapse-retrospective cohort analysis of 141 cases Blood 86 1995 563a
23. R. Collins O. Shpilberg W. Drobyski Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 15 1997 433 444
24. R. Collins S. Wolff A. List Prospective multicenter trial of donor buffy coat infusion for relapsed hematologic malignancy post-allogeneic bone marrow transplantation (BMT) Blood 84 1994 333a
25. J. Cullis A. Barrett J. Goldman Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: Studies in antigen-processing defective cell lines Leukemia 8 1994 165 170
26. A. Datta A. Barret Y. Jiang Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions Bone Marrow Transplant 14 1994 517 524
27. W. Drobyski C. Keever M. Roth Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose Blood 82 1993 2310 2318
28. G. Elfenbein J. Graham-Pole R. Weiner Consequences of no prophylaxis for acute graft-versus-host disease after HLA-identical bone marrow transplantation [abstract] Blood 70 suppl 1 1987 305a
29. L. Faber van Luxemburg-Heijs A. W. Veenhof Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implications for graft-versus-leukemia reactivity Blood 86 1995 2821 2828
30. A. Fefer K. Sullivan P. Weiden Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation R. Truitt R. Gale Bortin M. Cellular Immunotherapy of Cancer 1987 AR Liss New York 401 408
31. F. Frassoni F. Fagioli M. Sessarego The effect of donor leucocyte infusion in patients with leukemia following allogeneic bone marrow transplantation Exp Hematol 20 1992 712
32. R. Gale R. Champlin How does bone-marrow transplantation cure leukaemia? Lancet 2 1984 28 30
33. R. Gale M. Horowitz R. Ash Identical-twin bone marrow transplants for leukemia Ann Intern Med 120 1994 646 652
34. S. Giralt J. Hester Y. Huh CD8+ depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia (CML) after allogeneic bone marrow transplantation (BMT): Graft vs leukemia without graft vs host disease (GVHD) Blood 84 1994 538a
35. S. Giralt J. Hester Y. Huh CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation Blood 86 1995 4337 4343
36. J. Goldman J. Apperley L. Jones Bone marrow transplantation for patients with chronic myeloid leukemia N Engl J Med 314 1986 202 207
37. J. Goldman R. Gale M. Horowitz Bone marrow transplantation for chronic myelogenous leukemia in chronic phase Ann Intern Med 108 1988 806 814
38. V. Gressler R. Weinkauff W. Franklin Modulation of the expression of major histocompatibility antigens on splenic hairy cells—differential effect upon in vitro treatment with alpha-2b-interferon, gamma-interferon, and interleukin-2 Blood 72 1988 1048 1053
39. E. Guinan J. Gribben V. Boussiotis Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity Blood 84 1994 3261 3282
40. M. Hauch M. Gazzola T. Small Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia Blood 75 1990 2250 2262
41. C. Helg E. Roux P. Beris Adoptive immunotherapy for recurrent CML after BMT Bone Marrow Transplant 12 1993 125 129
42. T. Hercend T. Takvorian A. Nowill Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation Blood 67 1986 722 728
43. B. Hertenstein M. Wiesneth J. Novotny Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation Transplantation 56 1993 1114 1118
44. C. Higano M. Brixey E. Bryant Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect Transplantation 50 1990 175 177
45. C. Higano W. Raskind M. Flowers Alpha Interferon (IFN) results in high complete cytogenetic response rate in patients with cytogenetic-only relapse of chronic myelogenous leukemia (CML) after marrow transplantation (BMT) Blood 82 suppl 1993 661a
46. C. Higano W. Raskind J. Singer Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation Blood 80 1992 1437 1442
47. M. Horowitz R. Gale P. Sondel Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555 562
48. Y. Jiang J. Cullis E. Kanfer T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia Bone Marrow Transplant 11 1993 133 138
49. Y. Jiang E. Kanfer D. MacDonald Graft versus leukaemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukaemia cells Bone Marrow Transplant 8 1991 253 258
50. B. Johnson R. Truitt A decrease in graft-vs-host disease without loss of graft-vs-leukemia reactivity after MHC matched bone marrow transplantation by selective depletion of donor NK cells in vivo Transplantation 54 1992 104 112
51. B. Johnson W. Drobyski R. Truitt Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease Bone Marrow Transplant 11 1993 329 336
52. T. Kloosterman A. Marten van Bekkum D. Graft-versus-leukemia in rate MHC-mismatched bone marrow transplantation is merely an allogeneic effect Bone Marrow Transplant 15 1994 583 590
53. T. Kloosterman M. Tielemans A. Martens Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia Bone Marrow Transplant 14 1994 15 22
54. H. Kolb deWitte T. J. Mittermuller Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation Blood 82 suppl 1993 840a
55. H. Kolb J. Mittermuller C. Clemm Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood 76 1990 2462 2465
56. H. Kolb J. Mittermuller H. Hertenstein Adoptive immunotherapy in human and canine chimeras-the role of Interferon alfa Semin Hematol 30 3 1993 37 39
57. H. Kolb A. Schattenberg J. Goldman Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 1995 2041 2050
58. M. Korbling D. Przepiorka Y. Huh Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts Blood 85 1995 1659 1665
59. R. Korngold J. Sprent T cell subsets and graft-versus-host disease Transplantation 44 1987 335 339
60. B. Leber I. Walker A. Rodriguez Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: Recovery complicated by initial pancytopenia and late dematomyositis Bone Marrow Transplant 12 1993 405 407
61. M. Lee H. Kantarjian M. Talpaz Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome positive chronic myelogenous leukemia following interferon therapy Br J Haematol 82 1992 708 714
62. J. Maciejewski C. Selleri S. Anderson Fas antigen expression on CD34+ human marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokine mediated hematopoietic supression in vitro Blood 85 1995 3183 3190
63. S. Mackinnon J. Hows J. Goldman Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia Blood 76 1990 2037 2045
64. S. Mackinnon E. Papadopoulos M. Carabasi Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease Blood 86 1995 1261 1268
65. D. Maraninchi D. Blaise B. Rio Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukaemias Lancet 2 1987 175 178
66. A. Marmont M. Horowitz R. Gale T-cell depletion of HLA-identical transplants in leukemia Blood 78 1991 2120 2130
67. P. Martin J. Hansen C. Buckner Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts Blood 66 1985 664 672
68. G. Mathe J. Amiel L. Schwarzenberg Adoptive immunotherapy of acute leukemia: Experimental and clinical results Cancer Res 25 1965 1525 1531
69. J. Mehta R. Powles S. Singhal Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation Bone Marrow Transplant 16 1995 133 137
70. R. Mitsuyasu R. Champlin R. Gale Treatment of donor bone marrow with monoclonal anti–T-cell antibody and complement for the prevention of graft-versus-host disease Ann Intern Med 105 1986 20 26
71. J. Molldrem S. Dermine K. Parker Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood 88 1996 2450 2457
72. M. Mrsic M. Horowitz K. Atkinson Second HA-identical sibling transplants for leukemia recurrence Bone Marrow Transplant 9 1992 269 275
73. E. Naparsteck R. Or A. Nagler T-cell–depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse Br J Haematol 89 1995 506 515
74. S. Nimer J. Giorgi J. Gajewski Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation Transplantation 57 1994 82 87
75. L. Odom C. August J. Githens Remission of relapsed leukaemia during a graft-versus-host reaction A “graft-versus-leukaemia reaction” in man? Lancet 2 1978 537 540
76. K. Oettel O. Wesly M. Albertini Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome–bearing (Ph1+) human leukemia lines can also recognize Ph1-cells from the same patient Blood 83 1994 3390 3402
77. J. Okunewick D. Kochiban L. Machen The role of CD4 and CD8 T-cells in the graft-versus-leukemia response in Rauscher murine leukemia Bone Marrow Transplant 8 1991 445 452
78. J. Okunewick D. Kochiban L. Machen Comparison of the effects of CD3 and CD5 donor T cell depletion on graft-versus-leukemia in a murine model for MHC-matched unrelated donor transplantation Bone Marrow Transplant 13 1994 11 18
79. J. Okunewick D. Kociban L. Machen Evidence for a possible role of asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia Bone Marrow Transplant 16 1995 451 456
80. H. Ozer S. George C. Schiffer Prolonged subcutaneous administration of recombinant a2b interferon in patients with previously untreated Philadelphia chromosome–positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583 Blood 82 1993 2975 2984
81. C. Peschel M. Aman G. Rudolf Regulation of the cytokine network by interferon: A potential mechanism of interferon in chronic myelogenous leukemia Semin Hematol 30 1993 28 31
82. D. Porter J. Antin Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation Leuk Lymphoma 17 1995 191 197
83. D. Porter J. Antin Adoptive immunotherapy in bone marrow transplantation S. Burakoff H. Deeg Ferrara J. Graft-versus-Host-Disease 1996 Marcel Dekker New York 733 754
84. D. Porter J. Antin Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions Winter J. Blood Stem Cell Transplantation 1997 Kluwer Academic Publishers Norwell, MA 57 86
85. D. Porter M. Roth S. Lee Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation Bone Marrow Transplant 18 1996 975 980
86. D. Porter M. Roth C. McGarigle Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia N Engl J Med 330 1994 100 106
87. D. Porter M. Roth C. McGarigle Induction of graft-vs-leukemia (GVL) reaction as therapy for relapsed leukemia after allogeneic bone marrow transplantation (BMT) J Cell Biochem 18B 1994 94a
88. J. Radich J. Sanders C. Buckner Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens J Clin Oncol 11 1993 304 313
89. J. Reittie D. Gottlieb H. Heslop Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy Blood 73 1989 1351 1358
90. M. Roth J. Antin R. Ash Prognostic significance of Philadelphia chromosome–positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia Blood 79 1992 276 282
91. M. Roth J. Antin E. Bingham Detection of Philadelphia chromosome–positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia Blood 74 1989 882 885
92. N. Schmitz P. Dreger M. Suttorp Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood 85 1995 1666 1672
93. P. Servida S. Rossini C. Traversari Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBV-induced lymphoma Blood 82 1993 214a
94. S. Slavin A. Ackerstein E. Kedar IL-2 activated cell-mediated immunotherapy: Control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2 Bone Marrow Transplant 6 suppl 1990 37 39
95. S. Slavin A. Ackerstein L. Weiss Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines Cancer Invest 10 1992 221 227
96. S. Slavin A. Eckerstein L. Weiss Adoptive immunotherapy in conjunction with bone marrow transplantation—amplification of natural host defense mechanisms against cancer by recombinant IL2 Nat Immun Cell Growth Reg 7 1988 180 184
97. S. Slavin E. Naparstek A. Nagler Graft vs leukemia (GVL) effects with controlled GVHD by cell mediated immunotherapy (CMI) following allogeneic bone marrow transplantation (BMT) Blood 82 1993 423a
98. S. Slavin E. Naparstek A. Nagler Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation Blood 87 1996 2195 2204
99. K. Smith Lowest dose interleukin-2 immunotherapy Blood 81 1993 1414 1423
100. R. Soiffer C. Murray R. Gonin Effect of low-dose interleukin-2 on disease relapse after T-cell–depleted allogeneic bone marrow transplantation Blood 84 1994 964 971
101. R. Soiffer C. Murray P. Mauch Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow J Clin Oncol 10 1992 1191 1200
102. J. Sosman K. Oettel S. Smith Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells Blood 75 1990 2005 2016
103. K. Sullivan H. Shulman Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: Case histories Transplant Proc 21 1989 51 62
104. K. Sullivan A. Fefer R. Witherspoon Graft-versus-leukemia in man: Relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation R. Truitt R. Gale Bortin M. Cellular Immunotherapy of Cancer 1987 AR Liss New York 391 399
105. K. Sullivan H. Deeg J. Sanders Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation Blood 67 1986 1172 1175
106. K. Sullivan R. Storb D. Buckner Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms N Engl J Med 320 1989 828 834
107. K. Sullivan R. Storb R. Witherspoon Deletion of immunosuppressive prophylaxis after marrow transplantation increases hyperacute graft-versus-host disease but does not influence chronic graft-versus-host disease or relapse in patients with advanced leukemia Clin Transplant 3 1989 5 11
108. K. Sullivan P. Weiden R. Storb Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia Blood 73 1989 1720 1728
109. M. Sykes V. Abraham M. Harty IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity J Immunol 150 1993 197 205
110. M. Sykes M. Harty G. Szot Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects Blood 83 1994 2560 2569
111. M. Sykes M. Romick D. Sachs Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells Proc Natl Acad Sci 87 1990 5633 5637
112. J. Szer A. Grigg G. Phillipos Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT Bone Marrow Transplant 11 1993 109 111
113. M. Talpaz H. Kantarjian R. Kurzrock Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome–positive patients Ann Intern Med 114 1991 532 538
114. ten Bosch G. A. Joosten J. Kessler Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide Blood 88 1996 3522 3527
115. G. Tricot D. Vesole S. Jagannath Graft-versus-myeloma effect: Proof of principle Blood 87 1996 1196 1198
116. R. Truitt A. Atasoylu Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow Bone Marrow Transplant 8 1991 51 58
117. R. Truitt B. Johnson C. McCabe Graft versus leukemia J. Ferrara H. Deeg Burakoff S. Graft-vs-Host-Disease 1997 Marcel Dekker New York 385 424
118. R. Truitt A. LeFever Shih C.-Y. Graft-versus-leukemia reactions: Experimental models and clinical trails R. Gale Champlin R. Progress in Bone Marrow Transplantation 1987 AR Liss New York 219 232
119. R. Truitt A. LeFever Shih C.-Y. Graft-vs-leukemia effect S. Burakoff H. Deeg J. Ferrara Atkinson K. Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment Vol 12 1990 Marcel Dekker New York 177 204
120. R. Truitt C. Shih A. Lefever Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo J Immunol 131 1983 2105 2058
121. L. Uharek B. Glass T. Gaska Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model Bone Marrow Transplant 12 1993 S57 S60
122. G. Upadhyaya S. Gupta S. Sih Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells J Clin Invest 88 1991 2131
123. van Rhee F. F. Lin J. Cullis Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse Blood 83 1994 3377 3383
124. L. Verdonck van Heugten H. J. Giltay Amplification of the graft-versus-leukemia effect in man by interleukin-2 Transplantation 51 1991 1120 1124
125. U. Vourka-Karussis D. Karussis A. Ackerstein Enhancement of a GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia Exp Hematol 23 1995 196 201
126. J. Wagner G. Santos S. Noga Bone marrow graft engineering by counterflow centrifugal elutriation: Results of a phase I–II clinical trial Blood 75 1990 1370 1377
127. H. Waldmann A. Polliak G. Hale Elimination of GVHD by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1) Lancet 2 1984 483 486
128. C. Walsh R. Hayashi D. Saffran Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection J Immunol 156 1996 2645 2656
129. P. Weiden N. Flournoy Donnall Thomas E. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts N Engl J Med 300 1979 1068 1073
130. P. Weiden R. Storb M. Tsoi Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance J Immunol 116 1978 1212 1219
131. P. Weiden K. Sullivan N. Flournoy Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation N Engl J Med 304 1981 1529 1533
132. L. Weiss S. Reich S. Slavin Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. Treatment of murine leukemia in conjunction with allogenic bone marrow transplantation and IL2-activated cell-mediated immunotherapy Cancer Invest 10 1992 19 26
133. L. Weiss M. Weigensberg S. Morecki Characterization of effector cells of graft-vs-leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia Cancer Immunol Immunother 31 1990 236 242
134. J. Young E. Papadopoulos I. Cunningham T-cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission Blood 79 1992 3380 3387